Correspondence Address: Prof. Haijian Zhang, Rsearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, and Department of Immunology, Medical School of Nantong University, No. 20 West Temple Road, Nantong 226001, Jiangsu, China.
E-mail: [email protected]; Prof. Yi Zhou, Department of General Surgery, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, China. E-mail: [email protected]
Received: 5 July 2025 | Revised: 9 September 2025 | Accepted: 9 September 2025
Abstract
The study titled "Oncolytic virus VG161 in refractory hepatocellular carcinoma" presents a promising advancement in third-line therapy for advanced hepatocellular carcinoma (HCC). VG161, derived from an oncolytic herpes simplex virus, is engineered to express IL-12, IL-15, IL-15R, and a fusion protein that blocks the PD-1/PD-L1 pathway. In the multicenter phase 1 clinical trial, VG161 exhibited both strong efficacy and safety. This paper summarizes the study's findings, discusses potential limitations, and proposes directions for future research.
Keywords
Advanced HCC, oncolytic virus, TME
Cite This Article
Hong Y, Cui X, Chang R, Song S, Qian L, Zhu H, Tan L, Hong Z, Yi M, Zhou Y, Zhang H. Oncolytic virus VG161 brings new hope for advanced HCC. Hepatoma Res 2025;11:[Accept]. http://dx.doi.org/10.20517/2394-5079.2025.34
Cite This Article 0 clicks
